Study of 124I-NM404 in Advanced Solid Malignancies
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
Interventions: DRUG: 124I-NM404
Sponsor: University of Wisconsin, Madison
Collaborators: Cellectar Biosciences, Inc.